• How do you choose among different BTK inhibitors for treating CLL?

  • Dec 2 2022
  • Duración: 7 m
  • Podcast

How do you choose among different BTK inhibitors for treating CLL?

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • The Lymphoma Hub was pleased to speak with Francesc Bosch, Vall d’Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, How do you choose among different BTK inhibitors for treating CLL?


    Bosch opens by outlining common BTK inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib, noting that comparable efficacy and activity rates can cause difficulty when determining the most appropriate treatment; however, safety profiles vary. Bosch goes on to suggest that other factors, such as patient comorbidities, may be more useful; for example, the varying cardiovascular toxicity of BTK inhibitors may be pertinent when treating patients with comorbid cardiovascular conditions.

    Hosted on Acast. See acast.com/privacy for more information.
    Más Menos
Más Menos
adbl_web_global_use_to_activate_webcro768_stickypopup

Lo que los oyentes dicen sobre How do you choose among different BTK inhibitors for treating CLL?

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles